<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248065</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 001</org_study_id>
    <secondary_id>1U10HL098115</secondary_id>
    <nct_id>NCT01248065</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma</brief_title>
  <acronym>VIDA</acronym>
  <official_title>Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out if taking vitamin D in addition to an asthma
      controller medication helps to prevent worsening of asthma symptoms and asthma attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind parallel group trial that will enroll individuals who have
      vitamin D insufficiency and asthma with persistent symptoms despite low-dose inhaled
      corticosteroid. Participants on low-dose inhaled corticosteroid will be randomized to add-on
      therapy with either placebo or high-dose vitamin D for a 28-week period. During the inhaled
      corticosteroid-stable phase, participants will remain on low-dose inhaled corticosteroid.
      During the inhaled corticosteroid-taper phase, participants will taper their inhaled
      corticosteroid by 50% at two time-points post-randomization. The investigators will determine
      if the addition of vitamin D reduces the likelihood of treatment failure when compared to
      placebo during both the inhaled corticosteroid-stable and inhaled corticosteroid-taper phases
      of the study. Given the high prevalence of both vitamin D insufficiency and asthma, this
      trial has high potential to impact daily asthma management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>Twenty-eight week intervention period from randomization until end of trial.</time_frame>
    <description>Treatment failure is a well-defined asthma outcome reflecting overall asthma control that has been used previously in multiple clinical trials. Treatment failure as defined in the current proposal and prior trials is consistent with the American Thoracic Society (ATS)/European Respiratory Society(ERS) definition of a moderate exacerbation - a deterioration in symptoms and/or lung function with increased rescue bronchodilator use that lasts 2 days or more. The percentages of participants experiencing a treatment failure are Kaplan-Meier estimates of failure rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung Function Change From Baseline</measure>
    <time_frame>Change is measured as value at 28 weeks minus baseline value.</time_frame>
    <description>FEV1 (liters) and methacholine PC20 will be evaluated. Changes are measured as 28 weeks minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>Overall exacerbation rate during 28-week trial</time_frame>
    <description>Outcome defined as number of exacerbations per person-year.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Ciclesonide + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide + Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>vitamin D (100,000 IU loading dose followed by 4,000 IU/day)</description>
    <arm_group_label>Ciclesonide + Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
    <arm_group_label>Ciclesonide + placebo</arm_group_label>
    <arm_group_label>Ciclesonide + Vitamin D</arm_group_label>
    <other_name>Alvesco®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 years of age and older

          -  Physician-diagnosed asthma for at least previous 12 months

          -  Asthma confirmed by: (a) β-agonist reversibility of forced expiratory volume in 1
             second (FEV1) ≥12 % following 180 mcg (4 puffs) levalbuterol at visit 1 OR (b)
             methacholine provocative concentration causing a 20% fall in FEV1 (PC20) ≤ 8 mg/ml if
             not receiving an inhaled corticosteroid or ≤ 16 mg/ml if receiving an inhaled
             corticosteroid at visit 2. Source documentation for PC20 from an AsthmaNet
             methacholine challenge completed within 6 months of visit 2 will be accepted.

          -  Stable asthma controller therapy (inhaled corticosteroid or leukotriene modifier only)
             dose for past 2 weeks

          -  FEV1 ≥ 50% of predicted at visit 1

          -  Vitamin D level of less than 30 ng/ml at visit 0

          -  Experienced no more than one treatment failure in the VIDA run-in or oral
             corticosteroid (OCS) response periods on previous enrollments

          -  For women of childbearing potential: not pregnant, non-lactating, and agree to
             practice an adequate birth control method for the duration of the study

        Exclusion Criteria:

          -  Taking vitamin D supplements containing &gt; 1000 IU/day of vitamin D

          -  Taking &gt;2500 mg/day calcium supplements

          -  Chronic oral corticosteroid therapy

          -  Chronic inhaled corticosteroid therapy &gt; 1,000 mcg of fluticasone daily or the
             equivalent

          -  History of physician-diagnosed nephrolithiasis

          -  Use of concomitant medications that alter vitamin D metabolism - phenytoin,
             phenobarbital, cardiac glycosides; or absorption - orlistat, cholestyramine,
             colestipol; or those that interfere with study endpoints

          -  Impaired renal function (GFR &lt; 30 ml/min)

          -  Asthma exacerbation within past 4 weeks requiring systemic corticosteroids

          -  Respiratory tract infection within past 4 weeks

          -  Chronic diseases (other than asthma)

          -  History of cigarette smoking within the past 1 year or &gt; 10 pack years total

          -  Serum calcium greater than 10.2 mg/dl on entry

          -  Urine calcium/creatinine ratio greater than 0.37 (urinary Ca and Creat in mg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T. Mauger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennsylvania State University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lewis Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julian Solway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Moy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Sorkness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Bade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sally Wenzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Chmiel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Castro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Homer Boushey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monica Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Gerald Teague, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig LaForce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Carolina Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Fitzpatrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry Krishnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center/Stroger Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Sinai Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <results_first_submitted>June 18, 2014</results_first_submitted>
  <results_first_submitted_qc>July 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2014</results_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Principal Investigator, AsthmaNet Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Treatment failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciclesonide + Placebo</title>
          <description>Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
        </group>
        <group group_id="P2">
          <title>Ciclesonide + Vitamin D</title>
          <description>Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181">All 207 participants were included in the primary time-to-event analysis.</participants>
                <participants group_id="P2" count="179">All 201 participants were included in the primary time-to-event analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Third treatment failure event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciclesonide + Placebo</title>
          <description>Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
        </group>
        <group group_id="B2">
          <title>Ciclesonide + Vitamin D</title>
          <description>Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="408"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="12.7"/>
                    <measurement group_id="B2" value="39.9" spread="13.1"/>
                    <measurement group_id="B3" value="39.7" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of asthma</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="12.8"/>
                    <measurement group_id="B2" value="24.9" spread="13.5"/>
                    <measurement group_id="B3" value="25.0" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="9.5"/>
                    <measurement group_id="B2" value="32.0" spread="8.2"/>
                    <measurement group_id="B3" value="31.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom score (morning)</title>
          <units>Avg score of 5 sx: 0=absent to 3=severe</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.41" spread="0.36"/>
                    <measurement group_id="B2" value="0.41" spread="0.34"/>
                    <measurement group_id="B3" value="0.41" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom score (afternoon and evening)</title>
          <units>Avg score of 5 sx: 0=absent to 3=severe</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.43" spread="0.40"/>
                    <measurement group_id="B2" value="0.44" spread="0.35"/>
                    <measurement group_id="B3" value="0.43" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Level of 25-hydroxyvitamin D</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" lower_limit="13.4" upper_limit="23.7"/>
                    <measurement group_id="B2" value="19.9" lower_limit="14.5" upper_limit="25.0"/>
                    <measurement group_id="B3" value="19.2" lower_limit="13.9" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 before albuterol use (L)</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.62" spread="0.83"/>
                    <measurement group_id="B2" value="2.63" spread="0.78"/>
                    <measurement group_id="B3" value="2.63" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 before albuterol use (% predicted)</title>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.5" spread="14.2"/>
                    <measurement group_id="B2" value="80.7" spread="13.8"/>
                    <measurement group_id="B3" value="80.6" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Methacholine PC20 (mg/mL)</title>
          <units>mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.85" spread="1.67"/>
                    <measurement group_id="B2" value="2.05" spread="1.61"/>
                    <measurement group_id="B3" value="1.95" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sputum eosinophils (%)</title>
          <units>% of eosinophils</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.40" lower_limit="0" upper_limit="1.30"/>
                    <measurement group_id="B2" value="0.30" lower_limit="0" upper_limit="1.30"/>
                    <measurement group_id="B3" value="0.40" lower_limit="0" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure</title>
        <description>Treatment failure is a well-defined asthma outcome reflecting overall asthma control that has been used previously in multiple clinical trials. Treatment failure as defined in the current proposal and prior trials is consistent with the American Thoracic Society (ATS)/European Respiratory Society(ERS) definition of a moderate exacerbation - a deterioration in symptoms and/or lung function with increased rescue bronchodilator use that lasts 2 days or more. The percentages of participants experiencing a treatment failure are Kaplan-Meier estimates of failure rate.</description>
        <time_frame>Twenty-eight week intervention period from randomization until end of trial.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide + Placebo</title>
            <description>Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide + Vitamin D</title>
            <description>Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure</title>
          <description>Treatment failure is a well-defined asthma outcome reflecting overall asthma control that has been used previously in multiple clinical trials. Treatment failure as defined in the current proposal and prior trials is consistent with the American Thoracic Society (ATS)/European Respiratory Society(ERS) definition of a moderate exacerbation - a deterioration in symptoms and/or lung function with increased rescue bronchodilator use that lasts 2 days or more. The percentages of participants experiencing a treatment failure are Kaplan-Meier estimates of failure rate.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="O2" value="28" lower_limit="21" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lung Function Change From Baseline</title>
        <description>FEV1 (liters) and methacholine PC20 will be evaluated. Changes are measured as 28 weeks minus baseline.</description>
        <time_frame>Change is measured as value at 28 weeks minus baseline value.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide + Placebo</title>
            <description>Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide + Vitamin D</title>
            <description>Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Function Change From Baseline</title>
          <description>FEV1 (liters) and methacholine PC20 will be evaluated. Changes are measured as 28 weeks minus baseline.</description>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.11" upper_limit="0.03"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.14" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbations</title>
        <description>Outcome defined as number of exacerbations per person-year.</description>
        <time_frame>Overall exacerbation rate during 28-week trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide + Placebo</title>
            <description>Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide + Vitamin D</title>
            <description>Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations</title>
          <description>Outcome defined as number of exacerbations per person-year.</description>
          <units>Exacerbations/person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.30" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.18" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ciclesonide + Placebo</title>
          <description>Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
        </group>
        <group group_id="E2">
          <title>Ciclesonide + Vitamin D</title>
          <description>Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Ciclesonide: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe leg pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sigmoid diverticulitis with abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastric volvulus causing gastric outlet obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Limb edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Initial diagnosis of breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Benign fibroid tumor surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the digestive system</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="207"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Symptoms, signs, and ill-defined conditions</sub_title>
                <counts group_id="E1" events="114" subjects_affected="60" subjects_at_risk="207"/>
                <counts group_id="E2" events="141" subjects_affected="59" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious and parasitic diseases</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="207"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury and poisoning</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="207"/>
                <counts group_id="E2" events="40" subjects_affected="28" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the musculoskeletal system and connective tissue</sub_title>
                <counts group_id="E1" events="46" subjects_affected="31" subjects_at_risk="207"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the nervous system and sense organs</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="207"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the genitourinary system</sub_title>
                <counts group_id="E1" events="31" subjects_affected="18" subjects_at_risk="207"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diseases of the respiratory system</sub_title>
                <counts group_id="E1" events="231" subjects_affected="122" subjects_at_risk="207"/>
                <counts group_id="E2" events="253" subjects_affected="137" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tonya S. King, PhD</name_or_title>
      <organization>Penn State University Dept. of Public Health Sciences</organization>
      <phone>717-531-7178</phone>
      <email>tking@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

